Logo
x

Search

Subscribe Now

akeso

China’s NMPA Accepts NDA for Akeso’s Gumokimab to Treat Moderate to Severe Psoriasis

China’s NMPA Accepts NDA for Akeso’s Gumokimab to Treat Moderate to Severe Psoriasis

  • January 27, 2025
Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

Akeso Highlights the P-II Trial Data of Perioperative Ivonescimab for NSCLC at WCLC 2024

  • September 9, 2024
Akeso Reports Positive Results of Cadonilimab in P-III study for the treatment of Cervical Cancer

Akeso Reports Positive Results of Cadonilimab in P-III study for the treatment of Cervical Cancer

  • November 28, 2023
Akeso Published P-Ia/Ib Study (COMPASSION-01) Results of Cadonilimab for Solid Tumors in Cell Reports Medicine

Akeso Published P-Ia/Ib Study (COMPASSION-01) Results of Cadonilimab for Solid Tumors in Cell Reports Medicine

  • October 20, 2023
Akeso Reports the First Patient Dosing of Ivonescimab in P-III Trial as 1L Treatment of Squamous Non-Small Cell Lung Cancer

Akeso Reports the First Patient Dosing of Ivonescimab in P-III Trial as 1L Treatment of Squamous Non-Small Cell Lung Cancer

  • August 21, 2023
Akeso's Ivonescimab Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Non-Small-Cell Lung Carcinoma

Akeso's Ivonescimab Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Non-Small-Cell Lung Carcinoma

  • November 14, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.